BeyondSpring Inc (BYSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeyondSpring Inc (BYSI) has a cash flow conversion efficiency ratio of 0.236x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($-23.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BeyondSpring Inc market cap and net worth for the company's overall valuation and market capitalisation.
BeyondSpring Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BeyondSpring Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeyondSpring Inc ranked by their cash flow conversion efficiency. See BYSI operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fridenson
TA:FRDN
|
-0.054x |
|
MetalsTech Limited
F:MT1
|
-0.085x |
|
AMICCOM Electronics
TWO:5272
|
-0.057x |
|
Galva Technologies Tbk PT
JK:GLVA
|
0.582x |
|
Konsortium Transnasional Bhd
KLSE:4847
|
0.060x |
|
Tali Resources Ltd
AU:TR2
|
N/A |
|
Senetas Corporation Ltd
AU:SEN
|
-0.024x |
|
U Power Limited Ordinary Shares
NASDAQ:UCAR
|
-0.118x |
Annual Cash Flow Conversion Efficiency for BeyondSpring Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of BeyondSpring Inc from 2014 to 2025. View BYSI stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.99 Million | $-20.02 Million | 0.835x | -27.49% |
| 2024-12-31 | $-14.29 Million | $-16.44 Million | 1.151x | +63.93% |
| 2023-12-31 | $-23.46 Million | $-16.47 Million | 0.702x | -92.50% |
| 2022-12-31 | $-3.01 Million | $-28.15 Million | 9.362x | +514.63% |
| 2021-12-31 | $20.92 Million | $-47.24 Million | -2.258x | -373.93% |
| 2020-12-31 | $91.82 Million | $-43.74 Million | -0.476x | +69.21% |
| 2019-12-31 | $31.13 Million | $-48.16 Million | -1.547x | -136.33% |
| 2018-12-31 | $-9.38 Million | $-39.95 Million | 4.259x | +514.63% |
| 2017-12-31 | $28.04 Million | $-28.80 Million | -1.027x | +7.78% |
| 2016-12-31 | $12.30 Million | $-13.70 Million | -1.114x | -63.72% |
| 2015-12-31 | $9.66 Million | $-6.57 Million | -0.680x | -657.57% |
| 2014-12-31 | $-9.39 Million | $-1.15 Million | 0.122x | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more